LKB1 is mutated in ~20 % of NSCLC and this work, subsequently validated in Lkb1 mutant mouse models, suggests that metabolism based therapeutics may be effective in this subset of cancer patients. The gene discussed is STK11; the disease is non-small cell lung carcinoma.